Approaches Beyond Classic CAR T-Cells – Module 2

Program Overview

Navigating the Frontier of Hematologic Malignancy Therapies (2 of 5 Modules)

This activity provides an overview of novel approaches to T-cell immunotherapy, particularly the development of “off-the-shelf” T-cell therapies in the management of lymphomas and other hematologic malignancies.

Credit Expired
0.5 CE Credit(s)
Expires: March 12, 2024

Target Audience

Hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify potential T-cell immunotherapeutic strategies for the treatment of lymphomas and other hematologic malignancies

Activity Faculty

Heslop, Helen-Faculty Headshot-135x135

Helen E. Heslop, MD, DSc (Hon) (Chair)

Professor, Departments of Medicine and Pediatrics
Director, Center for Cell and Gene Therapy
Dan L. Duncan Chair
Interim Director, Dan L. Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, TX

Supporter Statement

The educational portion of this program is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP. Additional funding provided by The Leukemia & Lymphoma Society.

Provider Statement

This activity is jointly provided by The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.

Disclosure of Financial Relationships

Faculty

Planners and Managers

Disclosure of Financial Relationships 

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. 

Faculty 

Helen E. Heslop, MD, DSc, has relevant financial relationships with Allovir, Kiadis, Marker Therapeutics (Stockholder); Ankarys Therapeutics, Fresh Wind Biotechnologies, Gilead Biosciences, GSK, Immunai, Millennium, Novartis, Tessa Therapeutics (Advisor); Kuur Therapeutics, Tessa Therapeutics (Grant/Research Support).

All of the relevant financial relationships listed for this individual have been mitigated according to RMEI policies. 

Planners and Managers

All planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement 

In support of improving patient care, this activity has been planned and implemented by RMEI Medical Education, LLC and The Leukemia & Lymphoma Society. RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Credit Designation

Physician Credit Designation 
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Participation and Credit 

In order to receive credit, users must: 

  • Read the learning objectives and faculty disclosures 
  • Participate in the activity 
  • Complete the activity evaluation

 
There is no fee to participate.  

Method of Participation and Request for Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | www.RMEI.com | (866) 770-RMEI

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources